Hutchison China MediTech, Ltd.
NASDAQ:
LSE:
HCM
HCM
Hutchison China MediTech, Ltd., known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialization of targeted therapies and immunotherapies in oncology and immunological diseases.
Chi-Med's Innovation Platform, known as Hutchison MediPharma, has been the main driver of creating and developing its portfolio of drug candidates since 2002. It has about 550 scientists and staff focusing on discovering, developing, and commercializing targeted therapeutics and immunotherapies in oncology and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world.
Chi-Med has also developed a profitable Commercial Platform, which manufactures, markets, and distributes prescription drugs and consumer health products in China.
Key Facts
Auditor
Public Listing
Domicile
HQ/Management
Location of Key Operations
IR Contact
Pricewaterhousecoopers Zhong Tian LLP
IPO (March 17, 2016)
Cayman Islands
Hong Kong
Internal
852-2121-8200
Analyst Coverage
Latest News
June 17, 2021: HUTCHMED Launches Hong Kong Initial Public Offering // HUTCHMED (hutch-med.com)
March 4, 2021: Hutchison China MediTech Limited (HCM) Q4 2020 Earnings Call Transcript
March 4, 2021: Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity
March 4, 2021: Hutchison China MediTech Ltd. to Host Earnings Call
February 3, 2021: Chi-Med to Announce 2020 Final Results
January 14, 2021: Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC
January 11, 2021: Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases